PlainRecalls
FDA Devices Moderate Class II Ongoing

ADVIA Centaur Enhanced Estradiol (eE2) (REF) 500T - In vitro diagnostic use in the quantitative detection of estradiol SMN: 10697757 All lots

Reported: May 11, 2022 Initiated: March 3, 2022 #Z-1025-2022

Product Description

ADVIA Centaur Enhanced Estradiol (eE2) (REF) 500T - In vitro diagnostic use in the quantitative detection of estradiol SMN: 10697757 All lots

Reason for Recall

Falsely Elevated Results Observed with Plasma Specimens, could lead a clinician to misinterpret patient results

Details

Units Affected
88 units
Distribution
Worldwide distribution - US Nationwide and the countries of Austria, Belgium, Brazil, Bulgaria, Burkina, Faso Country AG, Cyprus, Denmark, Egypt, Estonia, Finland, France, French Polynesia, Georgia, Greece, Guadeloupe, India, Ireland, Israel, Italy, Kazakhstan, Latvia, Lithuania, Macedonia, Malta, Morocco, Nepal, Netherlands, Norway, Palestinian Ter, Paraguay, Poland, Portugal, Qatar, Romania, Russian Fed., Slovakia, Spain, Sweden, Switzerland, Turkey, Turkmenistan, U.A.E., Ukraine, United Kingdom, Vatican city.
Location
East Walpole, MA

Frequently Asked Questions

What product was recalled?
ADVIA Centaur Enhanced Estradiol (eE2) (REF) 500T - In vitro diagnostic use in the quantitative detection of estradiol SMN: 10697757 All lots. Recalled by Siemens Healthcare Diagnostics, Inc.. Units affected: 88 units.
Why was this product recalled?
Falsely Elevated Results Observed with Plasma Specimens, could lead a clinician to misinterpret patient results
Which agency issued this recall?
This recall was issued by the FDA Devices on May 11, 2022. Severity: Moderate. Recall number: Z-1025-2022.